

SYMTUZA® (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) Use of SYMTUZA in Patients Co-Infected with Hepatitis B or C

SUMMARY

- Patients coinfecting with HIV-1 and hepatitis B or C were excluded from phase 2-3 studies with SYMTUZA.¹

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) conducted on 07 July 2023 did not identify any relevant citations pertaining to this topic.

REFERENCE

1. Data on File. Summary of Clinical Safety Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination Tablet for the Treatment of HIV-1 Infection in Adults and Adolescents. Janssen Research & Development. EDMS-ERI-134922118; 2017.